PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma

• Dariusz Pytel ,

  Contributed equally to this work with: Dariusz Pytel, Yan Gao

  Affiliation Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America

  ⨯
• Yan Gao ,

  Contributed equally to this work with: Dariusz Pytel, Yan Gao

  Affiliation Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America

  ⨯
• Katarzyna Mackiewicz,

  Affiliation Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America

  ⨯
• Yuliya V. Katlinskaya,

  Affiliation Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

  ⨯
• Kirk A. Staschke,

  Affiliation Oncology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center dc1104, Indianapolis, Indiana, United States of America

  ⨯
• Maria C. G. Paredes,

  Affiliation Oncology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center dc1104, Indianapolis, Indiana, United States of America

  ⨯
• Akihiro Yoshida,

  Affiliation Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America

  ⨯
• Shuo Qie,

  Affiliation Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America

  ⨯
• Gao Zhang,

  Affiliation Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania, United States of America

  ⨯
• Olga S. Chajewski,

  Affiliation Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America

  ⨯
• Lawrence Wu,

  Affiliation Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania, United States of America

  http://orcid.org/0000-0002-8013-1275

  ⨯
• Ireneusz Majsterek,

  Affiliation Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, Lodz, Poland

  ⨯
• Meenhard Herlyn,

  Affiliation Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania, United States of America

  ⨯
• Serge Y. Fuchs,

  Affiliation Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

  ⨯
• J. Alan Diehl

  * E-mail: diehl@musc.edu

  Affiliation Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America

  ⨯